This observational study, called EpiDRIVE, is looking at how well targeted therapies like cetuximab, panitumumab, and bevacizumab work for people with metastatic colorectal cancer (mCRC). Researchers are studying your blood samples taken before treatment to find special markers in your cell-free DNA (cfDNA) that might predict if these treatments will be effective for you. They are looking at specific changes in your DNA called 5mC and 5hmC. The goal is to develop a test that can help doctors choose the best treatment for you. To join, you need to have mCRC, have received one of these targeted therapies, and have a pre-treatment blood sample available. The study will track how long you live without your cancer getting worse (Progression-Free Survival) for up to 36 months.

Study design

This is an observational study planning to include 500 participants with metastatic colorectal cancer. It is not a treatment study, but rather looks at existing data and samples.

What's involved

You would need to have a pre-treatment plasma sample available for cfDNA analysis. The study will also use your documented radiologic response evaluations.

Compensation

Not stated in the trial record.

Follow-up

Your Progression-Free Survival will be measured for up to 36 months from when your therapy started.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.